Trial Profile
A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Therapeutic Use
- 06 Jul 2011 Planned end date changed from Jan 2011 to Feb 2012 as reported by ClinicalTrials.gov.
- 06 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Apr 2009 New trial record